At the time of writing, Dyne Therapeutics Inc [DYN] stock is trading at $11.90, up 1.19%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The DYN shares have gain 1.36% over the last week, with a monthly amount glided 10.39%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Dyne Therapeutics Inc [NASDAQ: DYN] stock has seen the most recent analyst activity on March 12, 2025, when BMO Capital Markets initiated its Outperform rating and assigned the stock a price target of $50. Previously, Scotiabank started tracking the stock with Sector Outperform rating on March 07, 2025, and set its price target to $50. On December 13, 2024, Robert W. Baird initiated with a Outperform rating and assigned a price target of $46 on the stock. RBC Capital Mkts started tracking the stock assigning a Outperform rating and suggested a price target of $45 on November 26, 2024. JP Morgan downgraded its rating to a Neutral and reduced its price target to $35 on October 24, 2024. Chardan Capital Markets reiterated a Buy rating for this stock on May 21, 2024, and upped its price target to $42. In a note dated April 30, 2024, Morgan Stanley initiated an Overweight rating and provided a target price of $40 on this stock.
For the past year, the stock price of Dyne Therapeutics Inc fluctuated between $6.36 and $47.45. Currently, Wall Street analysts expect the stock to reach $47 within the next 12 months. Dyne Therapeutics Inc [NASDAQ: DYN] shares were valued at $11.90 at the most recent close of the market. An investor can expect a potential return of 294.96% based on the average DYN price forecast.
Analyzing the DYN fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.51, Equity is -0.53 and Total Capital is -0.58. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Dyne Therapeutics Inc [NASDAQ:DYN] has a current ratio of 20.35. Further, the Quick Ratio stands at 20.35, while the Cash Ratio is 13.94.
Transactions by insiders
Recent insider trading involved Scalzo Richard William, Officer, that happened on May 16 ’25 when 2479.0 shares were purchased. Officer, Beskrovnaya Oxana completed a deal on May 16 ’25 to buy 2589.0 shares. Meanwhile, Chief Commercial Officer Friedl-Naderer Johanna sold 143.0 shares on Mar 13 ’25.
